Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

doi:10.1200/JCO.2010.28.6963

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Nov 2010

Sampson John H, Heimberger Amy B, Archer Gary E, Aldape Kenneth D, Friedman Allan H, Friedman Henry S, Gilbert Mark R, Herndon James E, McLendon Roger E, Mitchell Duane A, Reardon David A, Sawaya Raymond, Schmittling Robert J, Shi Weiming, Vredenburgh James J, Bigner Darell D

Abstract excerpt

PURPOSE: Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms. PATIENTS AND METHODS: A phase II, multicenter trial was undertaken...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Vaccines

Share to Chemotherapy, Adjuvant

Share to Dacarbazine

Share to DNA Modification Methylases

Share to Radiotherapy, Adjuvant

Share to Sample Size

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 20921459
DOI: 10.1200/JCO.2010.28.6963
PMCID: PMC3020702

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.PMID 20921459Read ↗

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.Semantic proximity Read ↗

Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomasSemantic proximity Read ↗

The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.Semantic proximity Read ↗

The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant GliomasSemantic proximity Read ↗

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.Semantic proximity Read ↗

Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escapeSemantic proximity Read ↗

Phase I study of repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab in patients with newly diagnosed, MGMT-unmethylated glioblastomaSemantic proximity Read ↗

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.Semantic proximity Read ↗

Epidermal growth factor receptor and variant III targeted immunotherapySemantic proximity Read ↗

Prospect of rindopepimut in the treatment of glioblastomaSemantic proximity Read ↗

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastomaSemantic proximity Read ↗

A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.